BioSpace News Archive

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 2023 Cantor Global Healthcare Conference.

The non-injectable insulin market comprises various insulin formulations designed for administration without injections.

QIAGEN announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction kits: the QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit, eco-friendlier versions of the RNeasy Plus Mini Kit and the All DNA/RNA Mini Kit.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (“Aires” or the “Company”), a company focused on scientifically-proven EMF modulation technology, announces the completion of a second and final tranche of its previously announced non-brokered private placement (the “Offering”) of convertible debenture units (the “Units”) at a price of $1,000 per Unit for gross proceeds of $717,000 through the ‎issuance of 717 Units, and paid finder’s fees of $11,100.

IQVIA™ announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions business unit.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced that it will participate in the Cantor Fitzgerald Annual Global Healthcare Conference.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA) for the Company’s Thermal Boost module for use in conjunction with TULSA-PRO®.

Precision Optics Corporation, Inc. today announced that it has scheduled a conference call to discuss fourth quarter and fiscal year 2023 financial results on Thursday, September 28, 2023.